Treatment of Tachycardia Without Lowering Blood Pressure

Initial Assessment and Management

The American College of Cardiology recommends beginning with vagal maneuvers as the first-line intervention for supraventricular tachycardia (SVT), including Valsalva maneuver or carotid sinus massage, with a success rate of approximately 28% 1, 3
Assessing hemodynamic stability is crucial, and if the patient is unstable, synchronized cardioversion is indicated, as recommended by the American College of Cardiology and the European Heart Journal 1, 4
Determining the type of tachycardia (narrow vs. wide complex) is essential, as it affects treatment choices, according to the American Heart Association and the European Heart Journal 5, 6

The American College of Cardiology recommends adenosine as the first-line pharmacological agent for SVT, with a recommended dose of 6 mg rapid IV bolus followed by saline flush, and a success rate of approximately 95% in terminating AVNRT cases 1, 2, 3
Adenosine has a very short half-life, resulting in minimal sustained hemodynamic effects, and is effective in terminating approximately 95% of AVNRT cases, as reported by the American College of Cardiology and the European Heart Journal 3, 4

For AVNRT, the American College of Cardiology recommends first attempting vagal maneuvers, followed by adenosine IV if unsuccessful, with a success rate of approximately 95%, as reported by the American College of Cardiology and the European Heart Journal 1, 3, 7
For atrial fibrillation/flutter with rapid ventricular response, esmolol is a reasonable option, but its use is not recommended due to lack of citation, however, metoprolol is recommended for ongoing management of recurrent symptomatic multifocal atrial tachycardia, as reported by the American Heart Association 3

The American College of Cardiology recommends considering synchronized cardioversion when the patient is hemodynamically unstable, when pharmacological therapy fails to terminate the tachycardia, or when drugs are contraindicated, as reported by the American College of Cardiology 1, 7

The American Heart Association recommends avoiding verapamil or diltiazem in patients with suspected ventricular tachycardia or pre-excited atrial fibrillation, as they may cause hemodynamic collapse, as reported by the European Heart Journal 5
The American College of Cardiology recommends monitoring vital signs closely when using any rate-controlling medications, as reported by the American College of Cardiology and the European Heart Journal 6